Peter Sundström

Universitetslektor och neurolog med inriktning mot multipel skleros (MS), forskar på miljöfaktorers betydelse för uppkomsten av MS.

Kontakt

peter.sundstrom@umu.se

Verksam vid

Universitetslektor, överläkare vid Institutionen för klinisk vetenskap Enhet: Neurovetenskaper

Norrlands universitetssjukhus, Umeå universitet, Klinisk vetenskap Umeå universitet, Klinisk vetenskap, 901 85 Umeå

Peter Sundström använder i sin forskning främst biobanksprover som är insamlade flera år innan sjukdomsdebut. I dessa prover analyseras blodmarkörer för miljöfaktorer som Epstein-Barr virus (EBV), Humant Herpesvirus 6 (HHV6), D-vitamin, övervikt i ungdomen och rökning. Vi använder också enkätdata och resultat av genetiska riskfaktorer för att studera hur dessa riskfaktorer samverkar i mekanismerna bakom MS.

Grundtanken är att studera dessa miljöfaktorer i prover tagna i låg ålder, under 20 års ålder, vilket är den tidsperiod då sjukdomsprocesser sannolikt börjar. I Sverige finns med diagnosregister och omfattande biobanker unika förutsättningar för den här typen av forskning, som sker i samarbete med flertalet universitetssjukhus i Sverige, prof Tomas Olssons forskargrupp på Karolinska Institutet, och DKFZ i Heidelberg. Resultaten kan vägleda satsningar på sjukdomsprevention i form av t ex tillskott av D-vitamin eller vaccination av riskgrupper.

Leptin levels are associated with multiple sclerosis risk

Multiple Sclerosis, Sage Publications 2021, Vol. 27, (1) : 19-27

Biström, Martin; Hultdin, Johan; Andersen, Oluf; et al.

Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'

Multiple Sclerosis, Sage Publications 2021, Vol. 27, (1) : 161-162

Biström, Martin; Hultdin, Johan; Sundström, Peter

Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis

Journal of Neurology

Boremalm, Malin; Sundström, Peter; Salzer, Jonatan

Epstein-Barr virus infection after adolescence and Human herpesvirus 6A as risk factors for multiple sclerosis

John Wiley & Sons 2020

Biström, Martin; Jons, Daniel; Engdahl, Elin; et al.

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS

Multiple Sclerosis, Sage Publications 2020, Vol. 26, (12) : 1532-1539

Granqvist, Mathias; Burman, Joachim; Gunnarsson, Martin; et al.

Intrathecal immunoreactivity in people with or without previous infectious mononucleosis

Acta Neurologica Scandinavica, John Wiley & Sons 2020, Vol. 142, (2) : 161-168

Jons, Daniel; Zetterberg, Henrik; Malmeström, Clas; et al.

Prevention of post-dural puncture headache: a randomized controlled trial

European Journal of Neurology, John Wiley & Sons 2020, Vol. 27 : 14-15

Salzer, Jonatan; Granåsen, Gabriel; Sundström, Peter; et al.

Prevention of post-dural puncture headache: a randomized controlled trial

European Journal of Neurology, Wiley-Blackwell 2020, Vol. 27, (5) : 871-877

Salzer, Jonatan; Granåsen, Gabriel; Sundström, Peter; et al.

High serum concentration of vitamin D may protect against multiple sclerosis

Multiple Sclerosis Journal, Experimental, Translational and Clinical, Sage Publications 2019, Vol. 5, (4)

Biström, Martin; Alonso-Magdalena, Lucia; Andersen, Oluf; et al.

Leptin levels are associated with multiple sclerosis risk

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 904-904

Biström, Martin; Hultdin, Johan; Andersen, O.; et al.

Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial

Acta Neurologica Scandinavica, Vol. 139, (5) : 462-468

de Flon, Pierre; Laurell, Katarina; Sundström, Peter; et al.

Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis

Frontiers in Immunology, Frontiers Media S.A. 2019, Vol. 10

Engdahl, Elin; Gustafsson, Rasmus; Huang, Jesse; et al.

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 316-317

Forsberg, L.; Kågström, S.; Fält, A.; et al.

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 316-316

Forsberg, L.; Kågström, S.; Fält, A.; et al.

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 536-537

Fält, A.; Kågström, S.; Forsberg, L.; et al.

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 327-328

Fält, A.; Kågström, S.; Forsberg, L.; et al.

Pilot study of intrathecal immunoreactivity in healthy people with or without previous infectious mononucleosis

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 667-668

Jons, D.; Zetterberg, H.; Malmeström, C.; et al.

Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

Multiple Sclerosis, Sage Publications 2019, Vol. 25 : 763-764

Kågström, S.; Fält, A.; Forsberg, L.; et al.

Inflammatory activity and vitamin D levels in an MS population treated with rituximab

Multiple Sclerosis Journal, Experimental, Translational and Clinical, Vol. 5, (1)

Linden, Johan; Granåsen, Gabriel; Salzer, Jonatan; et al.

Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk

Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, (34) : 16955-16960

Tengvall, Katarina; Huang, Jesse; Hellstrom, Cecilia; et al.

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls

PLoS ONE, Vol. 13, (2)

de Flon, Pierre; Söderström, Lars; Laurell, Katarina; et al.

Viremia preceding multiple sclerosis: Two nested case-control studies

Virology, Elsevier 2018, Vol. 520 : 21-29

Hultin, Emilie; Arroyo Mühr, Laila Sara; Bzhalava, Zurab; et al.

Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response

European Journal of Neurology, WILEY 2017, Vol. 24 : 577-577

Novakova, L.; Zetterberg, H.; Axelsson, M.; et al.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Neurology, LIPPINCOTT WILLIAMS & WILKINS 2017, Vol. 89, (22) : 2230-2237

Novakova, Lenka; Zetterberg, Henrik; Sundström, Peter; et al.

Effect of high-dose vitamin D-3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis

Multiple Sclerosis, Vol. 23, (3) : 395-402

Rosjo, Egil; Lossius, Andreas; Abdelmagid, Nada; et al.

Managing Epstein-Barr virus and other risk factors in MS-Future perspectives

Acta Neurologica Scandinavica, Vol. 136 : 31-33

Sundström, Peter

Managing Epstein-Barr virus and other risk factors in MS-Future perspectives

Acta Neurologica Scandinavica, John Wiley & Sons 2017, Vol. 136 : 31-33

Sundström, Peter

The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis

Multiple Sclerosis, Sage Publications 2017, Vol. 23, (8) : 1137-1147

Wickström, Anne; Fagerström, Maria; Wickström, Lucas; et al.

Late Epstein-Barr virus infection and a second virus are linked to multiple sclerosis risk

Multiple Sclerosis Journal, SAGE PUBLICATIONS LTD 2016, Vol. 22 : 187-187

Biström, Martin; Gustafsson, R.; Engdahl, E.; et al.

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

Neurology, Vol. 87, (2) : 141-147

de Flon, Pierre; Gunnarsson, Martin; Laurell, Katarina; et al.

Selective and transient effect of vitamin D-3 supplementation on antibody responses against Epstein-Barr virus nuclear antigen 1 in relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal, SAGE PUBLICATIONS LTD 2016, Vol. 22 : 500-500

Rosjo, E.; Lossius, A.; Abdelmagid, N.; et al.

How to minimize the risk for headache?: a lumbar puncture practice questionnaire study

IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, Vol. 69, (11-12) : 397-402

Salzer, Jonatan; Rajda, Cecilia; Sundström, Peter; et al.

Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy

Neurology, Vol. 87, (20) : 2074-2081

Salzer, Jonatan; Svenningsson, Rasmus; Alping, Peter; et al.

Vitamin D and axonal injury in multiple sclerosis

Multiple Sclerosis, Vol. 22, (8) : 1027-1031

Sandberg, L.; Bistrom, M.; Salzer, Jonatan; et al.

Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis

Acta Neurologica Scandinavica, Wiley-Blackwell 2015, Vol. 131, (2) : 69-79

Jons, D; Sundström, Peter; Andersen, O

Are we minimizing the patients' risk for headache?: a lumbar puncture practice questionnaire study among European neurologists

Multiple Sclerosis, Vol. 21 : 733-734

Salzer, Jonatan; Rajda, C.; Sundström, Peter; et al.

Lumbar puncture preferences among Swedish neurologists.

Neurological Research, Vol. 37, (1) : 92-4

Salzer, Jonatan; Sundström, Peter; Vågberg, Mattias; et al.

Vitamin D and multiple sclerosis from epidemiology to prevention

Acta Neurologica Scandinavica, Vol. 132, (Supplement 199) : 56-61

Sundstrom, Peter; Salzer, Jonatan

Increasing prevalence of multiple sclerosis in Vasterbotten County of Sweden

Acta Neurologica Scandinavica, Vol. 132, (6) : 389-394

Svenningsson, Anders; Salzer, Jonatan; Vågberg, Mattias; et al.

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

Multiple Sclerosis, Sage Publications 2014, Vol. 20, (1) : 43-50

Axelsson, Markus; Malmeström, Clas; Gunnarsson, Martin; et al.

Vitamin D and multiple sclerosis: where do we go from here?

Expert Review of Neurotherapeutics, Informa 2014, Vol. 14, (1) : 9-18

Salzer, Jonatan; Biström, Martin; Sundström, Peter

The interaction between smoking and Epstein-Barr virus as multiple sclerosis risk factors may depend on age

Multiple Sclerosis, Sage Publications 2014, Vol. 20, (6) : 747-750

Salzer, Jonatan; Stenlund, Hans; Sundström, Peter

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Multiple Sclerosis, Vol. 20, (2) : 165-173

Sundqvist, E; Bergström, T; Daialhosein, H; et al.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

Neurology, Vol. 83, (22) : 2099-2100

Svenningsson, Anders; Sundström, Peter; Salzer, Jonatan; et al.

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

Multiple Sclerosis, Sage Publications 2013, Vol. 19, (11, Supplement: S) : 543-543

Axelsson, Markus; Malmeström, Clas; Gunnarsson, Martin; et al.

Vitamin A and systemic inflammation as protective factors in multiple sclerosis

Multiple Sclerosis, Sage Publications 2013, Vol. 19, (8) : 1046-1051

Salzer, Jonatan; Hallmans, Göran; Nyström, Maria; et al.

Smoking as a risk factor for multiple sclerosis

Multiple Sclerosis, Sage Publications 2013, Vol. 19, (8) : 1022-1027

Salzer, Jonatan; Hallmans, Göran; Nyström, Maria; et al.

Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank sampels

Multiple Sclerosis Journal, Sage Publications 2013, Vol. 19, (12) : 1587-1591

Salzer, Jonatan; Nyström, Maria; Hallmans, Göran; et al.

Timing of cigarette smoking as a risk factor for multiple sclerosis

Therapeutic advances in neurological disorders, Sage Publications 2013, Vol. 6, (3) : 205-205

Salzer, Jonatan; Sundström, Peter

Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention

Biomarkers in Medicine, Vol. 7, (2) : 193-195

Sundström, Peter; Salzer, Jonatan

Visa publikationer i DiVA